Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

• the present disclosure generally relates to compounds having enzyme inhibitory activity, pharmaceutical compositions comprising the compound, and methods of using the compounds for treating cancer and/or proliferative disorders.
• the c-Abl protein is a tightly regulated nonreceptor tyrosine kinase that is involved in the regulation of cell proliferation, cell survival, cell adhesion, cell migration and apoptosis.
• the c-Abl protein is located both in the nucleus and the cytoplasm. In the nucleus, c-Abl protein is known to be activated in response to DNA damage and contributes to apoptosis (Wang, 2000). Cytoplasmic c-Abl is associated with growth factor receptor signaling that can affect cell mobility and cell adhesion (Taagepera et al., 1998). The oncogenic effects of Abl are believed to reside in cytoplasmic forms of c-Abl.
• c-Abl is downregulated in part by intramolecular interactions that provide autoinhibitory kinase effects (Pendergast, 2002; Pluk et al., 2002; Hantschel et al., 2003).
• c-Abl kinase activity is regulated by intermolecular interactions with negative regulators, which include Bcr (Liu et al., 1996; Ling et al., 2003), PAG (Wen and Van Etten, 1997), F-actin (Woodring et al., 2003) and phosphoinositides (Plattner and Pendergast, 2003).
• the c-Abl protein is widely expressed in all tissues and until recently oncogenically activated forms of Abl were believed to be restricted to hematopoietic malignancies, principally chronic myeloid leukemia (CML) and to a lesser degree in acute lymphocytic B-cell leukemia.
• CML chronic myeloid leukemia
• Ph Philadelphia chromosome
• the Ph fuses 50 portions of BCR to the second exon of the c-ABL gene.
• the first exon of c-ABL encodes sequences involved in the autoinhibition of the c-Abl tyrosine kinase, so deletion of these sequences is thought to contribute to the activated state of the Abl tyrosine kinase domain.
• KIT also called CD 117
• the enzyme KIT is a receptor tyrosine kinase expressed on a wide variety of cell types.
• the KIT molecule contains a long extracellular domain, a transmembrane segment, and an intracellular portion.
• the ligand for KIT is stem cell factor (SCF), whose binding to the extracellular domain of KIT induces receptor dimerization and activation of downstream signaling pathways.
• SCF stem cell factor
• KIT mutations generally occur in the DNA encoding the juxtumembrane domain (exon 11). They also occur, with less frequency, in exons 7, 8, 9, 13, 14, 17, and 18. Mutations make KIT function independent of activation by SCF, leading to a high cell division rate and possibly genomic instability.
• Mutant KIT has been implicated in the pathogenesis of several disorders and conditions including systemic mastocytosis, GIST (gastrointestinal stromal tumors), AML (acute myeloid leukemia), melanoma, and seminoma. As such, there is a need for therapeutic agents that inhibit KIT, and especially agents that inhibit mutant KIT.
• Platelet-derived growth factor has been studied in relation to tumor angiogenesis binds to a large spectrum of mesoderm-derived cells such as fibroblasts, pericytes, glial or mesangial cells.
• PDGF isoforms bind two distinct receptors, PDGF-alpha and -beta, and this mechanism induces receptor autophosphorylation and activation of several signaling molecules.
• PDGF receptors are expressed in tumor cells and stromal cells in both normal and tumoral tissue. They play an important role in tumor progression as being part of a group of receptors that are expressed along the membrane of tumor cells (Adina Octavia Due et al.
• Non-Hodgkin lymphoma especially B cell lymphoma (BCLs), T cell lymphoma and natural killer cell lymphoma.
• PDGFRA D842V mutation has been found in a distinct subset of GIST, typically from the stomach.
• the D842V mutation is known to be associated with tyrosine kinase inhibitor resistance. As such, there is a need for agents that target this mutation. (Valentina et al., Int. J. Mol. Sci. 2018, 19, 732).
• the present disclosure provides a compound having c-abl, KIT and/or PDGFR inhibitory activity, a composition comprising the compound and a method useful to treat cancer and/or proliferative disorders.
• R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herebelow.
• compositions comprising a therapeutically effective amount of a compound described herein and a pharmaceutically acceptable carrier.
• the present disclosure provides methods of inhibiting or treating cancer and/or a proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds described herein.
• alkenyl refers to a straight or branched hydrocarbonyl group with at least one site of unsaturation, i.e., a carbon-carbon, sp2 double bond. In an embodiment, alkenyl has from 2 to 12 carbon atoms. In some embodiments, alkenyl is a C 2 —C 10 alkenyl group or a C 2 —C 6 alkenyl group. Examples of alkenyl group include, but are not limited to, ethylene or vinyl (CH ⁇ CH 2 ), allyl (—CH 2 CH ⁇ CH 2 ), cyclopentenyl (—C 5 H 7 ), and 5-hexenyl (—CH 2 CH 2 CH 2 CH 2 CH ⁇ CH 2 ).
• alkoxy is RO— where R is alkyl.
• alkoxy groups include methoxy, ethoxy and propoxy.
• alkoxyalkyl refers to an alkyl moiety substituted with an alkoxy group.
• alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl and ethoxyethyl.
• alkoxycarbonyl is ROC(O)—, where R is an alkyl group as defined herein. In various embodiments, R is a C 1 -C 10 alkyl group or a C 1 -C 6 alkyl group.
• alkyl refers to a straight or branched chain hydrocarbonyl group. In an embodiment, alkyl has from 1 to 12 carbon atoms. In some embodiments, alkyl is a C 1 -C 10 alkyl group or a C 1 -C 6 alkyl group. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl. “lower alkyl” means alkyl having from 1 to 4 carbon atoms.
• alkylamino refers to an amino group substituted with one or more alkyl groups.
• N-(alkyl)amino is RNH— and “N,N-(alkyl)2amino” is R 2 N—, where the R groups are alkyl as defined herein and are the same or different.
• R is a C 1 -C 10 alkyl group or a C 1 -C 6 alkyl group.
• alkylamino groups include methylamino, ethylamino, propylamino, butylamino, dimethylamino, diethylamino, and methylethylamno.
• alkylaminoalkyl refers to an alkyl moiety substituted with an alkylamino group, wherein alkylamino is as defined herein.
• alkylaminoakyl groups include methylaminomethyl and ethylaminomethyl.
• alkynyl refers to a straight or branched carbon-chain group with at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond. In an embodiment, alkynyl has from 2 to 12 carbon atoms. In some embodiments, alkynyl is a C 2 —C 10 alkynyl group or a C 2 —C 6 alkynyl group. Examples of alkynyl groups include acetylenic (—C ⁇ CH) and propargyl (—CH 2 C ⁇ CH).
• aryl refers to any monocyclic or bicyclic carbon ring of up to 7 atoms in each ring, wherein at least one ring is aromatic, or an aromatic ring system of 5 to 14 carbon atoms which includes a carbocyclic aromatic group fused with a 5-or 6-membered cycloalkyl group.
• Representative examples of aryl groups include, but are not limited to, phenyl, tolyl, xylyl, naphthyl, tetrahydronaphthyl, anthracenyl, fluorenyl, indenyl, azulenyl and indanyl.
• a carbocyclic aromatic group can be unsubstituted or optionally substituted.
• cycloalkyl is a hydrocarbyl group containing at least one saturated or partially unsaturated ring structure, and attached via a ring carbon. In various embodiments, it refers to a saturated or a partially unsaturated C 3 —C 12 cyclic moiety, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl and cyclooctyl.
• Cycloalkyloxy is RO—, where R is cycloalkyl.
• halogen and “halo” refers to chloro (—Cl), bromo (—Br), fluoro (—F) or iodo (—I).
• Haloalkoxy refers to an alkoxy group substituted with one or more halo groups and examples of haloalkoxy groups include, but are not limited to, —OCF 3 , —OCHF 2 and —OCH 2 F.
• Haloalkoxyalkyl refers to an alkyl moiety substituted with a haloalkoxy group, wherein haloalkoxy is as defined herein.
• haloalkoxyalkyl groups include trifluoromethoxymethyl, trifluoroethoxymethyl and trifluoromethoxyethyl.
• Haloalkyl refers to an alkyl moiety substituted with one or more halo groups. Examples of haloalkyl groups include —CF 3 and CHF 2 .
• heteroalkyl refers to a straight- or branched-chain alkyl group having from 2 to 14 carbons (in some embodiments, 2 to 10 carbons) in the chain, one or more of which has been replaced by a heteroatom selected from S, 0, P and N.
• exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, amides, alkyl sulfides, and the like.
• heterocyclyl includes the heteroaryls defined below and refers to a saturated or partially unsaturated monocyclic, bicyclic or tricyclic group of 2 to 14 ring-carbon atoms and, in addition to ring-carbon atoms, 1 to 4 heteroatoms selected from P, N, O and S.
• the heterocyclic group is attached to another moiety through carbon or through a heteroatom, and is optionally substituted on carbon or a heteroatom.
• heterocyclyl examples include azetidinyl, benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl,
• 3- or 4-membered heterocyclyl refers to a monocyclic ring having 3 or 4 ring atoms wherein at least one ring atom is heteroatom selected from the group consisting of N, O and S.
• Non-limiting examples of 3- or 4-membered heterocyclyl include aziridinyl, 2H-azirinyl, oxiranyl, thiiranyl, azetidinyl, 2,3-dihyroazetyl, azetyl, 1,3-diazetidinyl, oxetanyl, 2H-oxetyl, thietanyl, and 2H-thietyl.
• heteroaryl refers to a monocyclic, bicyclic or tricyclic ring having up to 7 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms in the ring selected from the group consisting of N, O and S.
• heteroaryl examples include pyridyl, thienyl, furanyl, pyrimidyl, imidazolyl, pyranyl, pyrazolyl, thiazolyl, thiadiazolyl, isothiazolyl, oxazolyl, isoxazoyl, pyrrolyl, pyridazinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzofuranyl, dibenzofuranyl, dibenzothiophenyl, benzothienyl, indolyl, benzothiazolyl, benzooxazolyl, benzimidazolyl, isoindolyl, benzotriazolyl, purinyl, thianaphthenyl and pyrazinyl.
• heteroaryl can occur via an aromatic ring, or, if heteroaryl is bicyclic or tricyclic and one of the rings is not aromatic or contains no heteroatoms, through a non-aromatic ring or a ring containing no heteroatoms.
• Heteroaryl is also understood to include the N-oxide derivative of any nitrogen containing heteroaryl.
• Heteroaryloxy is RO—, where R is heteroaryl.
• hydroxyalkoxy refers to an alkoxy group substituted with a hydroxyl group (OH), wherein alkoxy is as defined herein.
• alkoxy is as defined herein.
• An example of hydroxyalkoxy is hydroxyethoxy.
• hydroxyalkyl refers to a linear or branched monovalent C 1 -C 10 hydrocarbon group substituted with at least one hydroxy group and examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl.
• the term “pharmaceutically acceptable” means suitable for use in pharmaceutical preparations, generally considered as safe for such use, officially approved by a regulatory agency of a national or state government for such use, or being listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
• pharmaceutically acceptable carrier refers to a diluent, adjuvant, excipient, or carrier, or other ingredient which is pharmaceutically acceptable and with which a compound of the invention is administered.
• pharmaceutically acceptable salt refers to a salt which may enhance desired pharmacological activity.
• pharmaceutically acceptable salts include acid addition salts formed with inorganic or organic acids, metal salts and amine salts.
• acid addition salts formed with inorganic acids include salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid.
• Examples of acid addition salts formed with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxy-benzoyl)-benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethane-sulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methyl-bicyclo[2.2.2]oct-2-ene1-carbox
• the term “therapeutically effective amount” means when applied to a compound of the invention is intended to denote an amount of the compound that is sufficient to ameliorate, palliate, stabilize, reverse, slow or delay the progression of a disorder or disease state, or of a symptom of the disorder or disease.
• the method of the present invention provides for administration of combinations of compounds.
• the “therapeutically effective amount” is the amount of a compound of the present invention in the combination sufficient to cause the intended biological effect.
• treatment means ameliorating or reversing the progress or severity of a disease or disorder, or ameliorating or reversing one or more symptoms or side effects of such disease or disorder.
• Treatment or “treating”, as used herein, also means to inhibit or block, as in retard, arrest, restrain, impede or obstruct, the progress of a system, condition or state of a disease or disorder.
• treatment or “treating” further means an approach for obtaining beneficial or desired clinical results, where “beneficial or desired clinical results” include, without limitation, alleviation of a symptom, diminishment of the extent of a disorder or disease, stabilized (i.e., not worsening) disease or disorder state, delay or slowing of a disease or disorder state, amelioration or palliation of a disease or disorder state, and remission of a disease or disorder, whether partial or total.
• the compounds of Formula (I) are used for modulating the activity of a protein kinase c-abl, KIT and PDGFR.
• modulating refers to the alteration of the catalytic activity of a protein kinase.
• modulating refers to the activation or inhibition of the catalytic activity of a protein kinase, depending on the concentration of the compound or salt to which the protein kinase is exposed or, more preferably, the inhibition of the catalytic activity of a protein kinase.
• catalytic activity refers to the rate of phosphorylation of tyrosine, serine or threonine under the influence, direct or indirect, of a protein kinase.
• Type I or “DFG-in” ATP competitive inhibitors, which directly compete with ATP in the ATP binding site (i.e., Src and Abl inhibitor dasatinib
• Type II or “DFG-out” ATP competitive inhibitors, which, in addition to binding the ATP binding site also engage an adjacent hydrophobic binding site that is only accessible when the kinase is in an inactivated configuration (i.e., the activation loop is oriented in a conformation that would block substrate binding) (i.e., imatinib, nilotinib), and (3) non-ATP competitive inhibitors that bind at sites outside the ATP binding site that affect the activity of the kinase (i.e. GNF-2).
• GNF-2 non-ATP competitive inhibitors that bind at sites outside the ATP binding site that affect the activity of the kinase
• the phrase “compound(s) of this/the disclosure” includes any compound(s) of Formula (I), as well as clathrates, hydrates, solvates, or polymorphs thereof. And, even if the term “compound(s) of the disclosure” does not mention its pharmaceutically acceptable sat, the term includes salts thereof.
• the compounds of this disclosure include stereochemically pure compounds, e.g., those substantially free (e.g., greater than 85% ee, greater than 90% ee, greater than 95% ee, greater than 97% ee, or greater than 99% ee) of other stereoisomers.
• the compounds of Formula (I) according to the present disclosure or salts thereof are tautomeric isomers and/or stereoisomers (e.g., geometrical isomers and conformational isomers), such isolated isomers and their mixtures also are included in the scope of this disclosure. If the compounds of the present disclosure or salts thereof have an asymmetric carbon in their structures, their active optical isomers and their racemic mixtures also are included in the scope of this disclosure.
• polymorph refers to solid crystalline forms of a compound of this disclosure or complex thereof. Different polymorphs of the same compound can exhibit different physical, chemical and/or spectroscopic properties. Different physical properties include, but are not limited to stability (e.g., to heat or light), compressibility and density (important in formulation and product manufacturing), and dissolution rates (which can affect bioavailability).
• Differences in stability can result from changes in chemical reactivity (e.g., differential oxidation, such that a dosage form discolors more rapidly when comprised of one polymorph than when comprised of another polymorph) or mechanical characteristics (e.g., tablets crumble on storage as a kinetically favored polymorph converts to thermodynamically more stable polymorph) or both (e.g., tablets of one polymorph are more susceptible to breakdown at high humidity).
• chemical reactivity e.g., differential oxidation, such that a dosage form discolors more rapidly when comprised of one polymorph than when comprised of another polymorph
• mechanical characteristics e.g., tablets crumble on storage as a kinetically favored polymorph converts to thermodynamically more stable polymorph
• both e.g., tablets of one polymorph are more susceptible to breakdown at high humidity.
• Different physical properties of polymorphs can affect their processing. For example, one polymorph might be more likely to form solvates or might be more difficult to filter or wash free of impurities than another
• solvate means a compound or its salt according to this disclosure that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces.
• Preferred solvents are volatile, non-toxic, and/or acceptable for administration to humans in trace amounts.
• hydrate means a compound or its salt according to this disclosure that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
• clathrate means a compound or its salt in the form of a crystal lattice that contains spaces (e.g., channels) that have a guest molecule (e.g., a solvent or water) trapped within.
• spaces e.g., channels
• guest molecule e.g., a solvent or water
• R 1 is cyclopropyl, cyclobutyl, or 4-membered heterocyclyl, wherein R 1 is optionally substituted with one or more groups selected from the group consisting of halo, alkyl, hydroxyalkyl, haloalkyl, and monoalkylaminoalkyl,
• R 2 and R 3 are independently —H, halo, alkyl, alkoxy, —CF 3 ,—CHF 2 , —CH 2 F, or —OCF 3 ,
• R 4 is aryl, heteroaryl, cycloalkyl, heterocyclyl, or heteroalkyl, wherein R 4 is optionally substituted with one or more groups selected from the group consisting of halo, hydroxyl, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, hydroxyalkyl, dialkylaminoalkyl, trimethylsilylethoxymethyl, —CH 2 NHC(O)CH 3 , —NO 2 , —NR a R b , —NR a C( ⁇ O)R b , —NR a C( ⁇ O)NR a R b , —NR a C( ⁇ O)OR b , —OR a , —CN, —C( ⁇ O)R a , —C( ⁇ O)OR a , —C( ⁇ O)NR a R b , —OC( ⁇ O)R a , —OC(
• R 5 is H, halo, or alkyl.
• R 1 is cyclopropyl or cyclobutyl, wherein R 1 is optionally substituted with one or more groups selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl and C 1 -C 3 haloalkyl;
• R 2 and R 3 are independently —H, halo, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, —CF 3 , —CHF 2 , —CH 2 F, or —OCF 3 ;
• R 4 is aryl, heteroaryl, cycloalkyl, or heterocyclyl, wherein R 4 is optionally substituted with one or more groups selected from the group consisting of halo, hydroxyl, C 1 -C 3 alkyl, C 2 —C 3 alkenyl, C 2 —C 3 alkynyl, C 3 —C 4 cycloalkyl, C 1 -C 3 haloalkyl
• R 1 is cyclopropyl or cyclobutyl, wherein R 1 is optionally substituted with one or more groups selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl and C 1 -C 3 haloalkyl.
• R 1 is cyclopropyl, fluorocyclopropyl, hydroxycyclopropyl, hydroxymethylcyclopropyl, difluorocyclopropyl, methylaminomethylcyclopropyl, cyclobutyl, fluorocyclobutyl, or difluorocyclobutyl.
• R 1 is cyclopropyl, fluorocyclopropyl, cyclobutyl, or fluorocyclobutyl.
• R 1 is 4-membered heterocyclyl which is optionally substituted with one or more groups selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl and C 1 -C 3 haloalkyl.
• the 4-membered heterocyclyl is selected from the group consisting of aziridinyl, 2H-azirinyl, oxiranyl, thiiranyl, azetidinyl, 2,3-dihyroazetyl, azetyl, 1,3-diazetidinyl, oxetanyl, 2H-oxetyl, thietanyl, and 2H-thietyl.
• R 2 and R 3 are independently H, methyl, or fluoro.
• R 4 is phenyl, pyridinyl, pyrimidinyl, indolinyl, pyrazolyl, thiazolyl, oxoindolinyl, pyrrolopyridinyl, pyrazolyl, pyrazolopyridinyl, oxodihydropyrrolopyridinyl, oxodihydrobenzothiazolyl, benzoimidazolyl, bezooxazolyl, beznothiazolyl, thiophenyl, pyrrolopyridinyl or isothiazolyl, wherein R 4 is optionally substituted with one or more groups selected from the group consisting of halo, alkyl, alkenyl, alkynyl, hydroxyalkyl, amino, cyano, acetyl, hydroxy, and haloalkyl.
• R 4 is fluoro-methylphenyl, fluoro-hydroxymethylphenyl, chloro-hydroxymethylphenyl, methyl-hydroxymethylphenyl, difluoro-hydroxymethylphenyl, chloro-fluoro-hydroxymethylphenyl, fluoro-methyl-hydroxymethylphenyl, chloro-methylphenyl, dimethylphenyl, acetamido-methylphenyl, hydroxy-methylphenyl, hydroxypropanyl-methylphenyl, methyl-propenylphenyl, methyl-pyridinylethynylphenyl, methyl-pyrrolylphenyl, methyl-thiazolylphenyl, imidazolyl-methylphenyl, cyano-methylphenyl, methyl-pyrazolylphenyl, ethynyl-methylphenyl, methylpyridinyl, fluoro-methyl-methylaminophenyl, dimethylpyridinyl, fluoro-methylmethylmethyl, flu
• R 4 is fluoro-methylphenyl, fluoro-hydroxymethylphenyl, chloro-hydroxymethylphenyl, methyl-hydroxymethylphenyl, difluoro-hydroxymethylphenyl, chloro-fluoro-hydroxymethylphenyl, fluoro-methyl-hydroxymethylphenyl, chloro-methylphenyl, dimethylphenyl, acetam ido-methylphenyl, hydroxyl-methylphenyl, methyl-propenylphenyl, ethynyl-methylphenyl, fluoro-methyl-methylaminophenyl, fluoro-hydroxyl-methylphenyl, methyl-methylaminophenyl, methyl-pyrrolylphenyl, methyl-thiazolylphenyl, cyano-methylphenyl, imidazolyl-methylphenyl, methylpyridinyl, chloro-methylpyridinyl, fluoro-methylpyridinyl, fluoromethyl-methyl-methyl-
• R 4 is pyridinyl or phenyl that has one or more substitutions selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, halo, hydroxyl, hydroxyalkyl, haloalkyl, cyano, amino, alkoxy, alkoxyalkoxyalkyl, alkoxyalkyl, and haloalkoxy.
• R 4 is selected from the group consisting of:
• R 1 is cyclopropyl, fluorocyclopropyl, difluorocyclopropyl, cyclobutyl, fluorocyclobutyl, or difluorocyclobutyl;
• R 2 and R 3 are independently H, methyl, or fluoro; and
• R 4 is fluoro-methylphenyl, fluoro-hydroxymethylphenyl, chloro-methylphenyl, dimethylphenyl, acetamido-methylphenyl, hydroxyl-methylphenyl, methyl-propenylphenyl, ethynyl-methylphenyl, fluoro-methyl-methylaminophenyl, methyl-pyrrolylphenyl, methyl-thiazolylphenyl, cyano-methylphenyl, imidazolyl-methylphenyl, methylpyridinyl, chloro-methylpyridinyl, fluoro-methylpyridinyl, fluoromethyl-methylpyridiny
• the compounds described herein have c-abl inhibition activity and selectivity against c-abl.
• the compounds are effective to treat cancer and/or a proliferative disorder.
• R 1 is cyclopropyl, fluorocyclopropyl, cyclobutyl, fluorocyclobutyl, or difluorocyclobutyl;
• R 2 and R 3 are H;
• R 4 is phenyl, pyridinyl, pyrazolyl, pyrrolopyridinyl, indolinyl, oxoindolinyl, bezothiazolyl, benzoimidazolyl, benzooxazolyl, or thiophenyl, wherein R 4 is optionally substituted with one or more groups selected from the group consisting of halo, hydroxyl, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, alkoxyalkyl, alkoxyalkoxy, alkylaminoalkyl, —NR a R b , —NR a C( ⁇ O)R b , —OR a , -SR a , —
• R 1 is fluorocyclopropyl, and such compounds include, but are not limited to, the following compounds and salts thereof:
• R 1 is fluorocyclopropyl
• R 2 and R 3 are H
• R 4 is phenyl, indolinyl, oxoindolinyl, or benzothiazolyl, wherein R 4 is optionally substituted with one or more groups selected from the group consisting of halo, hydroxyl, alkyl, alkylamino, and pyrrolyl
• R 5 is —H, halo, or C 1 -C 3 alkyl.
• such compounds include, but are not limited to, the following compounds and salts thereof:
• the compound of Formula (I) is selected from compounds according to Formula (II) and pharmaceutically acceptable salts thereof:
• R 6 is selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl and C 1 -C 3 haloalkyl and R 2 , R 3 , R 4 , and R 5 are as defined above.
• the compound of Formula (I) is a compound of which R 1 is cyclopropyl.
• the compound of Formula (I) is N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide or a salt thereof.
• the compound of Formula (I) is a compound of which R 1 is cyclobutyl which is optionally substituted with one or more groups selected from the group consisting of halo, alkyl, hydroxyalkyl, haloalkyl, and monoalkylaminoalkyl; and R 2 , R 3 , R 4 , and R 5 are as defined above.
• the compound of Formula (I) is selected from the group consisting of the following compounds and salts thereof:
• the compounds of the present disclosure include stereoisomers of the compounds described herein.
• the compounds are stereochemically pure compounds such as those substantially free (e.g., greater than 85% ee, greater than 90% ee, greater than 95% ee, greater than 97% ee, or greater than 99% ee) of other stereoisomers.
• stereoisomers include, but are not limited to,
• R 2 , R 3 , R 4 , R 5 , and R 6 are as defined above.
• the compound of Formula (I) is selected from compounds according to Formula (III) and pharmaceutically acceptable salts thereof:
• R 6 is selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl and C 1 -C 3 haloalkyl and R 2 , R 3 , R 4 , and R 5 are as defined above.
• Table 1 shows exemplary compounds having the stereochemistry of Formula (III). Examples of the compound of Formula (III) include, but are not limited to, the following compounds and salts thereof:
• the compound of Formula (I) is selected from the group consisting of the following compounds and salts thereof:
• the present disclosure provides pharmaceutically acceptable salts of the compounds described above.
• the pharmaceutically acceptable salts are as defined above in the definition section.
• the salt is hydrochloric acid salt, tartaric acid salt, phosphoric acid salt, or maleic acid salt.
• the present disclosure further provides methods for treating cancer and/or proliferative disorders in a subject having or susceptible to having such a disease or disorder, by administering to the subject a therapeutically effective amount of one or more compounds as described above.
• the compound of the present disclosure for inhibiting c-abl, KIT and PDGFR activity is useful for treatment or prevention of cancer diseases and proliferative disorders.
• the compound can be used for inhibiting or hindering c-abl, KIT and/or PDGFR kinase activity, and for treating cancer diseases and proliferative disorders, or for preventing aggravation of such disease.
• the present disclosure provides a method for inhibiting or hindering c-abl, KIT and/or PDGFR activity in a cell, wherein the cell is contacted with an effective amount of a compound of the present disclosure.
• such cell is present in a subject (for example, CML patients).
• a medical use for treating or preventing cancer diseases and proliferative disorders in a subject using the compound according to the present disclosure.
• the method of the present disclosure comprises administering to a subject in need of treatment or prevention of cancer diseases and proliferative disorders with a pharmaceutical composition containing a therapeutically or prophylactically effective amount of c-abl, KIT and/or PDGFR inhibitor.
• the cancer diseases and proliferative disorders include, but is not limited to, breast cancer, ovarian cancer, NSCLC, acute lymphocytic leukemia acute myelogeneous leukemia, chronic myelogenous leukemia and chronic lymphocytic leukemia.
• the compounds also described herein can be useful for treating conditions associated with aberrant KIT activity, in humans or non-humans.
• Activating mutations in KIT are found in multiple indications, including systemic mastocytosis, GIST (gastrointestinal stromal tumors), AML (acute myeloid leukemia), melanoma, seminoma, intercranial germ cell tumors, and Non-Hodgkin lymphoma (NHL) such as B cell lymphoma (BCLs), T cell lymphoma and natural killer cell lymphoma.
• KIT chronic myelomonocytic leukemia
• Mastocytosis refers to a group of disorders characterized by excessive mast cell accumulation in one tissue, or in multiple tissues. Mastocytosis is subdivided into two groups of disorders: (1) cutaneous mastocytosis (CM) describes forms that are limited to the skin; and (2) systemic mastocytosis (SM) describes forms in which mast cells infiltrate extracutaneous organs, with or without skin involvement. SM is further subdivided into five forms: indolent (ISM), smoldering (SSM), aggressive (ASM), SM with associated hematologic non-mast cell lineage disease (SM-AHNMD), and mast cell leukemia (MCL).
• ISM indolent
• SSM smoldering
• ASM aggressive
• MCL mast cell leukemia
• Diagnosis of systemic mastocytosis is based in part on histological and cytological studies of bone marrow showing infiltration by mast cells of frequently atypical morphology, which frequently abnormally express non-mast cell markers (CD25 and/or CD2). Diagnosis of SM is confirmed when bone marrow mast cell infiltration occurs in the context of one of the following: (1) abnormal mast cell morphology (spindle-shaped cells); (2) elevated level of serum tryptase above 20 ng/mL; or (3) the presence of the activating KIT D816V mutation.
• Activating mutations at the D816 position are found in the vast majority of mastocytosis cases (90-98%), with the most common mutations being D816V and D816H, and D816Y.
• the D816V mutation is found in the activation loop of the kinase domain and leads to constitutive activation of KIT kinase.
• the compounds described herein may also be useful to treat GIST.
• Complete surgical resection remains the principal treatment of choice for patients with a primary GIST. Surgery is effective in approximately 50% of patients with GIST; of the remaining patients, tumor recurrence is frequent.
• Primary treatment with a KIT inhibitor such as imatinib has also been shown to be sufficient for initial treatment. However, resistance to imatinib occurs within months through somatic mutation. These secondary imatinib resistant mutations are most frequently located on Exon 11, 13, 14, 17 or 18.
• Sunitinib is the standard of care second line treatment for most imatinib resistant tumors and is effective for those containing mutations in exons 11, 13 and 14.
• the use of combinations of imatinib, sunitinib and/or regorafenib with the compounds disclosed herein may allow for the prevention of emergence of resistance to exon 17 mutations.
• the compounds described herein may also be useful in treating AML.
• AML patients harbor KIT mutations as well, with the majority of these mutations at the D816 position.
• the method above is used to treat gastrointestinal stromal tumor(GIST), GI tract cancers such as stomach cancer and colorectal cancer, melanoma, chronic lymphocytic leukemia (CLL), acute lymphocytic leukem ia(ALL), or acute myelogeneous leukemia(AML).
• the method is used to treat gastrointestinal stromal tumor(GIST), melanoma or chronic lymphocytic leukemia (CLL).
• Suitable subjects to be treated according to the present disclosure include mammalian subjects. Mammals according to the present disclosure include, but are not limited to, human, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. Subjects may be of either gender and at any stage of development. In one embodiment, the suitable subject to be treated according to the present disclosure is human.
• the compounds of the present disclosure are generally administered in a therapeutically effective amount.
• the compounds of the present disclosure can be administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
• An effective dosage is typically in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 0.01 to about 50 mg/kg/day, in single or divided doses. Depending on age, species and disease or condition being treated, dosage levels below the lower limit of this range may be suitable. In other cases, still larger doses may be used without harmful side effects. Larger doses may also be divided into several smaller doses, for administration throughout the day. Methods for determining suitable doses are well known in the art to which the present disclosure pertains. For example, Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000 can be used.
• the compounds described herein or pharmaceutically acceptable salts thereof can be administered as follows:
• the compounds of the present disclosure may be administered orally, including by swallowing, so that the compound enters the gastrointestinal tract, or absorbed into the blood stream directly from the mouth (e.g., buccal or sublingual administration).
• compositions for oral administration include solid, liquid, gel or powder formulations, and have a dosage form such as tablet, lozenge, capsule, granule or powder.
• compositions for oral administration may be formulated as immediate or modified release, including delayed or sustained release, optionally with enteric coating.
• Liquid formulations can include solutions, syrups and suspensions, which can be used in soft or hard capsules.
• Such formulations may include a pharmaceutically acceptable carrier, for example, water, ethanol, polyethylene glycol, cellulose, or an oil.
• the formulation may also include one or more emulsifying agents and/or suspending agents.
• the amount of drug present may be from about 0.05% to about 95% by weight, more typically from about 2% to about 50% by weight of the dosage form.
• tablets may contain a disintegrant, comprising from about 0.5% to about 35% by weight, more typically from about 2% to about 25% of the dosage form.
• disintegrants include, but are not limited to, lactose, starch, sodium starch glycolate, crospovidone, croscarmellose sodium, maltodextrin, or mixtures thereof.
• Suitable lubricants for use in a tablet, may be present in amounts from about 0.1% to about 5% by weight, and include, but are not limited to, talc, silicon dioxide, stearic acid, calcium, zinc or magnesium stearate, sodium stearyl fumarate and the like.
• Suitable binders for use in a tablet, include, but are not limited to, gelatin, polyethylene glycol, sugars, gums, starch, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and the like.
• Suitable diluents, for use in a tablet include, but are not limited to, mannitol, xylitol, lactose, dextrose, sucrose, sorbitol, microcrystalline cellulose and starch.
• Suitable solubilizers for use in a tablet, may be present in amounts from about 0.1% to about 3% by weight, and include, but are not limited to, polysorbates, sodium lauryl sulfate, sodium dodecyl sulfate, propylene carbonate, diethyleneglycol monoethyl ether, dimethyl isosorbide, polyethylene glycol (natural or hydrogenated) castor oil, HCORTM (Nikkol), oleyl ester, GelucireTM, caprylic/caprylic acid mono/diglyceride, sorbitan fatty acid esters, and Solutol HSTM.
• polysorbates sodium lauryl sulfate, sodium dodecyl sulfate, propylene carbonate, diethyleneglycol monoethyl ether, dimethyl isosorbide, polyethylene glycol (natural or hydrogenated) castor oil, HCORTM (Nikkol), oleyl ester, GelucireTM, caprylic/
• Compounds of the present disclosure may be administered directly into the blood stream, muscle, or internal organs.
• Suitable means for parenteral administration include intravenous, intra-muscular, subcutaneous intraarterial, intraperitoneal, intrathecal, intracranial, and the like.
• Suitable devices for parenteral administration include injectors (including needle and needle-free injectors) and infusion methods.
• compositions for parenteral administration may be formulated as immediate or modified release, including delayed or sustained release.
• Most parenteral formulations are aqueous solutions containing excipients, including salts, buffering agents and isotonic agents.
• Parenteral formulations may also be prepared in a dehydrated form (e.g., by lyophilization) or as sterile non-aqueous solutions. These formulations can be used with a suitable vehicle, such as sterile water. Solubility-enhancing agents may also be used in preparation of parenteral solutions.
• Topical or transdermal administration can include lotions, solutions, creams, gels, hydrogels, ointments, foams, implants, patches and the like.
• Pharmaceutically acceptable carriers for topical administration formulations can include water, alcohol, mineral oil, glycerin, polyethylene glycol and the like.
• Topical or transdermal administration can also be performed by electroporation, iontophoresis, phonophoresis and the like.
• compositions for topical administration may be formulated as immediate or modified release, including delayed or sustained release.
• a pharmaceutical composition according to the present disclosure may contain one or more additional therapeutic agents, for example, to increase the efficacy or decrease the side effects.
• a pharmaceutical composition further contains one or more additional therapeutic agents selected from active ingredients useful to treat or inhibit diseases mediated directly or indirectly by c-abl, c-abl, KIT and/or PDGFR kinase.
• active ingredients useful to treat or inhibit diseases mediated directly or indirectly by c-abl, c-abl, KIT and/or PDGFR kinase.
• active ingredients are, without limitation, agents such asimatinib, sunitinib and regorafenib.
• Other agents include the compounds described in WO 2014/039714 and WO 2014/100620.
• compositions for treating or preventing a disease or condition are well known in the art to which the present disclosure pertains.
• pharmaceutically acceptable excipients, carriers, additives and so on can be selected and then mixed with the compounds of the present disclosure for making the pharmaceutical compositions.
• the present disclosure provides a compound having various pharmacological effects by inhibiting c-abl, KIT and/or PDGFR activity, a pharmaceutical composition having the compound as an effective agent, a medical use, particularly for treating cancer diseases and proliferative disorders, of the compound, and a method of treatment or prevention comprising administering the compound to a subject in need of such treatment or prevention.
• the compounds of the present disclosure and pharmaceutically acceptable salts thereof have good safety and high selectivity for c-abl, KIT and/or PDGFR, and thus exhibit superior properties as a drug.
• Synthetic methods A to N were used to prepare the compounds of the following. Below, the illustrating synthetic examples of some compounds of the present disclosure are described, and other compounds can be prepared by the similar method to the one described below with different starting or reacting materials.
• Step 2) (1 S,2 S)-2-fluoro-N-(6-iodoimidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamide
• Example 1 A solution of Compound 4 (0.600 g, 1.833 mmol) in ethyl acetate (100 mL) was mixed at the room temperature with hydrochloric acid (1.00 M solution in EtOAc, 1.925 mL, 1.925 mmol). The reaction mixture was stirred at the same temperature for 3 hr. The precipitates were collected by filtration, washed by diethylether, and dried to give Example 1 as white solid (0.665 g, 99.7%).
• Step 1) (1 S,2 S)-N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1, 2-a]pyridin-2-yl)-2-fluorocyclopropane-1-carboxamide
• Example 1 A solution of Example 1 (0.060 g, 0.183 mmol) in acetonitrile (8 mL) was mixed at the room temperature with 1-chloropyrrolidine-2,5-dione (NCS, 0.027 g, 0.202 mmol), stirred at the same temperature for 3 hr, and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was washed with aqueous saturated sodium chloride solution, separated, dried (anhydrous MgSO 4 ), filtered, and concentrated in vacuo.
• NCS 1-chloropyrrolidine-2,5-dione
• Step 1) (1 S,2 S)-2-fluoro-N-(6-(2-methyl-5-(1 H-pyrazol-3-yl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamide
• Example 26 (0.100 g, 0.291 mmol), (1H-pyrazol-3-yl)boronic acid (0.042 g, 0.378 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (Pd(dtbpf)Cl 2 , 0.019 g, 0.029 mmol) and cesium carbonate (0.284 g, 0.873 mmol) in 1,4-dioxane (12 mL) /water (3 mL) was mixed at the room temperature and then heated at 140° C.
• Step 1) (1 S,2 S)-2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
• Step 1) 3-(2-((1 S,2 S)-2-fluorocyclopropane-1-carboxamido)imidazo[1, 2-a]pyridin-6-yl)-4-methylphenyl trifluoromethanesulfonate
• Step 2) (1 S,2 S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamide
• Step 1) (15,25)-2-fluoro-N-(6-(4,4, 5, 5-tetramethyl-1, 3,2-d ioxaborolan-2-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamide
• Step 2) (15 , 25)-2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl) imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
• Example 44 as white solid (0.031 g, 39.8%).
• Step 2) (1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-(methoxymethyl)phenyl) imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
• Example 66 (91.3 mg, 193.69 ⁇ mol, 53.03% yield, 100% purity, TFA) was obtained as a white solid.
• Step 2) (1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-(furan-2-yl)phenyl)imidazo[1, 2-a]pyridin-2-yl)cyclopropanecarboxamide
• Step 2) (1 S,2 S)-N-(6-(2-(acetam idomethyl)-3-fluorophenyl)imidazo[1, 2-a]pyridin-2-yl)-2-fluorocyclopropanecarboxamide
• Example 77 (15.3 mg, 29.84 ⁇ mol, 8.25% yield, 97.2% purity, TFA) was obtained as white solid
• Step 2 (15,25)-2-fluoro-N-(6-(3-fluoro-2-((2-methoxyethoxy)methyl) phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide.
• Example 84 (32.2 mg, 62.10 ⁇ mol, 9.18% yield, 99.4% purity, TFA) as an off-white solid.
• Step 3 (15 , 25)-2-fluoro-N-(6-(3-fluoro-2-((2-hydroxyethoxy)methyl)phenyl) imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
• trimethoxymethane (108.09 mg, 1.02 mmol, 111.66 ⁇ L, 1 eq) was added to the reaction mixture, then the reaction mixture was stirred at 90° C. for another 2 hr. The reaction mixture was concentrated under reduced pressure to remove solvent. Saturated aqueous solution of NaHCO 3 (50 mL) was added into the residue, then the mixture was extracted with ethyl acetate (30mL* 3), the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue. Compound 28 (160 mg, crude) was obtained as a brown solid.
• Table 1 shows the compounds of Examples along with general synthetic methods used to make the compound and characterization data.
• ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl 2 ), bovine serum albumin (BSA), ethylene glycol-bis(p-aminoethyl ether)-N,N,N′-tetraacetic acid (EGTA), triton X-100, 1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. HEPES buffer was purchased from Gibco. ABL1 kinase and Abltide were purchased from Signalchem.
• MgCl 2 Magnesium chloride
• BSA bovine serum albumin
• EGTA ethylene glycol-bis(p-aminoethyl ether)-N,N,N′-tetraacetic acid
• DTT 1,4-dithiothreitol
• DMSO dimethyl sulfoxide
• c-Abl kinase activity was measured by Promega's ADP-GloTM Assay.
• His-tagged recombinant human ABL1 (0.25 ng/ ⁇ l) is incubated with 5 ⁇ L of compounds (0.5% DMSO), 5 ⁇ L of Abltide (0.01 ⁇ g/ ⁇ l) and 5 ⁇ L of ATP (25 pM) in buffer (50 mM HEPES,7.5; 10 mM MgCl2; 1 mM EGTA; 0.05% BSA; 0.01% Triton X-100; 2 mM DTT.).
• the assay was started by incubating the reaction mixture in a 96-well plate at 30° C. for 30-min.
• ADP-Glo reagent was added and the reaction was incubated at room temperature for 40-min to stop the reaction and degrade residual ATP.
• the ADP product was then converted to ATP by adding 50 ⁇ L per well of detection reagent.
• Luminescence was detected after 30-min room temperature incubation with the Molecular device I3X plate reader.
• the IC50 values were calculated from a series of percent inhibition values determined at a range of inhibitor concentration using software routines as implemented in the GraphPad Prism 7 software and Sigma Plot 13.0.
• ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl 2 ), ethylene glycol-bis(8-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), manganese (II) chloride (MnCl 2 ), bovine serum albumin (BSA), 1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. HEPES buffer was purchased from Gibco. c-Kit kinase and poly (4:1 Glu, Tyr) peptide were purchased from Signalchem.
• c-Kit kinase activity was measured by Promega's ADP-GloTM Assay.
• 100ng of recombinant human c-Kit is incubated with 5 ⁇ L of compounds (0.5% DMSO), 5 ⁇ L of Poly (4:1 Glu, Tyr) peptide (50 ng/ ⁇ l) and 5 ⁇ L of ATP (50 ⁇ M) in buffer (50 mM HEPES, pH7.5; 10 mM MgCl 2 ; 1 mM EGTA; 0.05% BSA; 50 ⁇ M DTT; 2mM MnCl 2 ).
• the assay was started by incubating the reaction mixture in a 96-well plate at 30° C. for 120-min.
• ADP-Glo reagent was added and the reaction was incubated at room temperature for 40-min to stop the reaction and degrade residual ATP.
• the ADP product was then converted to ATP by adding 50 ⁇ L per well of detection reagent.
• Luminescence was detected after 30-min room temperature incubation with the Molecular device I3X plate reader.
• the IC50 values were calculated from a series of percent inhibition values determined at a range of inhibitor concentration using software routines as implemented in the GraphPad Prism 8 software and Sigma Plot 13.0.
• ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl 2 ), ethylene glycol-bis( ⁇ -aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), bovine serum albumin (BSA), 1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. HEPES buffer was purchased from Gibco. c-Kit (D816V) kinase and poly (4:1 Glu, Tyr) peptide were purchased from Signalchem.
• MgCl 2 Magnesium chloride
• EGTA ethylene glycol-bis( ⁇ -aminoethyl ether)-N,N,N′,N′-tetraacetic acid
• BSA bovine serum albumin
• DTT 1,4-dithiothreitol
• DMSO dimethyl sulfoxide
• c-Kit (D816V) kinase activity was measured by Promega's ADP-GIoTM Assay.
• 2.5ng of recombinant human c-Kit (D816V) is incubated with 5 ⁇ L of compounds (0.5% DMSO), 5 ⁇ L of Poly (4:1 Glu, Tyr) peptide (50 ng/ ⁇ l) and 5 ⁇ L of ATP (15 ⁇ M) in buffer (50 mM HEPES, pH7.5; 10 mM MgCl 2 ; 1 mM EGTA; 0.05% BSA; 50 ⁇ M DTT).
• the assay was started by incubating the reaction mixture in a 96-well plate at 30° C. for 120-min.
• ADP-Glo reagent was added and the reaction was incubated at room temperature for 40-min to stop the reaction and degrade residual ATP.
• the ADP product was then converted to ATP by adding 50 ⁇ L per well of detection reagent.
• Luminescence was detected after 30-min room temperature incubation with the Molecular device I3X plate reader.
• the IC50 values were calculated from a series of percent inhibition values determined at a range of inhibitor concentration using software routines as implemented in the GraphPad Prism 8 software and Sigma Plot 13.0.
• ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl 2 ), ethylene glycol-bis(p-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), bovine serum albumin (BSA), 1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. HEPES buffer was purchased from Gibco. PDGFR ⁇ Kinase and poly (4:1 Glu, Tyr) peptide were purchased from Signalchem.
• MgCl 2 Magnesium chloride
• EGTA ethylene glycol-bis(p-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
• BSA bovine serum albumin
• DTT 1,4-dithiothreitol
• DMSO dimethyl sulfoxide
• PDGFR ⁇ kinase activity was measured by Promega's ADP-GloTM Assay.
• 40ng of recombinant human PDGFR ⁇ is incubated with 5 ⁇ L of compounds (0.5% DMSO), 5 ⁇ L of Poly (4:1 Glu, Tyr) peptide (100 ng/ ⁇ l) and 5 ⁇ L of ATP (25 pM) in buffer (50 mM HEPES, pH7.5; 10 mM MgCl 2 ; 1 mM EGTA; 0.05% BSA; 50 ⁇ M DTT).
• the assay was started by incubating the reaction mixture in a 96-well plate at 30° C. for 60-min.
• ADP-Glo reagent was added and the reaction was incubated at room temperature for 40-min to stop the reaction and degrade residual ATP.
• the ADP product was then converted to ATP by adding 50 ⁇ L per well of detection reagent.
• Luminescence was detected after 30-min room temperature incubation with the Molecular device I3X plate reader.
• the IC 50 values were calculated from a series of percent inhibition values determined at a range of inhibitor concentration using software routines as implemented in the GraphPad Prism 8 software and Sigma Plot 13.0.
• ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl 2 ), ethylene glycol-bis(p-aminoethyl ether)-N, N, N′, N′-tetraacetic acid (EGTA), bovine serum albumin (BSA), 1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. HEPES buffer was purchased from Gibco. PDGFR ⁇ (D842V) Kinase and poly (4:1 Glu, Tyr) peptide were purchased from Signalchem.
• MgCl 2 Magnesium chloride
• EGTA ethylene glycol-bis(p-aminoethyl ether)-N, N, N′, N′-tetraacetic acid
• BSA bovine serum albumin
• DTT 1,4-dithiothreitol
• DMSO dimethyl sulfoxide
• PDGFR ⁇ (D842V) kinase activity was measured by Promega's ADP-GloTM Assay.
• 10 ng of recombinant human PDGFR ⁇ (D842V) is incubated with 5 ⁇ L of compounds (0.5% DMSO), 5 ⁇ L of Poly (4:1 Glu, Tyr) peptide (100 ng/ ⁇ l) and 5 ⁇ L of ATP (3 pM) in buffer (50 mM HEPES, pH7.5; 10 mM MgCl 2 ; 1 mM EGTA; 0.05% BSA; 50pM DTT).
• the assay was started by incubating the reaction mixture in a 96-well plate at 30° C. for 120-min.
• ADP-Glo reagent was added and the reaction was incubated at room temperature for 40-min to stop the reaction and degrade residual ATP.
• the ADP product was then converted to ATP by adding 50 ⁇ L per well of detection reagent.
• Luminescence was detected after 30-min room temperature incubation with the Molecular device I3X plate reader.
• the IC 50 values were calculated from a series of percent inhibition values determined at a range of inhibitor concentration using software routines as implemented in the GraphPad Prism 8 software and Sigma Plot 13.0.
• Table 2 shows IC 50 values of the invented compounds which represent +for >1000 nM, ++for 101-1000 nM, +++for 10-100 nM, ++++for ⁇ 10 nM.
• K562 human leukemia cell line purchased from Korean cell line bank (KCLB) and were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin in a humidified incubator in an atmosphere of 5% CO 2 at 37° C.
• Cells were seeded in 96-well plates at a density of 2 ⁇ 103 cells/well in 100 p1 media. Compounds were diluted as two times concentration in 100 ⁇ l of media and added to each well. Compounds were 5-fold serially diluted for 6 points and treated from 5 ⁇ M to 1.6 nM in K562 cells. After 48 hr incubation, Compound treated cells were analyzed for anti-proliferation assay.
• Cell viability was investigated using the Cell Titer 96 Aqueous One Solution Reagent. Briefly, 200 ⁇ l of media were supplemented with 40 ⁇ l of MTS solution, incubated for 4hr, and then the absorbance was recorded at 490 nm with a 96-well plate reader. G150 values were calculated from a series of percent of cell viability at a range of compound concentration. GraphPad Prism 8 software or SigmaPlot 13.0 was used to generate G150 values.
• Table 3 shows 1050 values of the invented compounds which represent +for >1000 nM, ++for 101-1000 nM, +++for 10-100 nM, ++++for ⁇ 10 nM.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Psychology (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=72141573

Family Applications (4)

Family Applications After (3)

Country Status (10)

Families Citing this family (10)

Citations (3)

Family Cites Families (22)

• 2020
  • 2020-02-21 AU AU2020224401A patent/AU2020224401A1/en not_active Abandoned
  • 2020-02-21 CN CN202080014118.3A patent/CN113454081B/zh active Active
  • 2020-02-21 MX MX2021010122A patent/MX2021010122A/es unknown
  • 2020-02-21 KR KR1020217030103A patent/KR102892275B1/ko active Active
  • 2020-02-21 WO PCT/IB2020/051469 patent/WO2020170205A1/en not_active Ceased
  • 2020-02-21 EP EP20759969.7A patent/EP3927706A4/en active Pending
  • 2020-02-21 JP JP2021549327A patent/JP7609790B2/ja active Active
  • 2020-02-21 US US17/432,497 patent/US20220242861A1/en not_active Abandoned
  • 2020-02-21 EP EP20759163.7A patent/EP3927705A4/en active Pending
  • 2020-02-21 IL IL285708A patent/IL285708B2/en unknown
  • 2020-02-21 US US16/797,140 patent/US11098044B2/en active Active
  • 2020-02-21 WO PCT/IB2020/051472 patent/WO2020170206A1/en not_active Ceased
  • 2020-02-21 CN CN202080014156.9A patent/CN113454082B/zh active Active
  • 2020-02-21 JP JP2021549328A patent/JP2022521537A/ja active Pending
  • 2020-02-21 CA CA3131059A patent/CA3131059A1/en active Pending
  • 2020-02-21 KR KR1020217030099A patent/KR20210122861A/ko not_active Withdrawn
• 2021
  • 2021-07-12 US US17/372,863 patent/US11802126B2/en active Active
• 2023
  • 2023-07-19 US US18/223,860 patent/US12534461B2/en active Active

Patent Citations (4)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events